Connect Biopharma posts investor presentation highlighting rademikibart program in asthma, COPD exacerbationsPUBT·Jul 13 at 07:22 PMCNTB-0.95%
Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watchrttnews·Jul 9 at 09:55 PMFBRX+0.20%CNTB-0.95%
Connect Biopharma Holdings (CNTB) Receives a New Rating from OppenheimerTip Ranks·Jul 9 at 12:25 PMCNTB-0.95%
Connect Biopharma shares are trading higher after Oppenheimer initiated its coverage on the stock with a Outperform rating and announced a price target of $8.benzinga_article·Jul 9 at 09:57 AMCNTB-0.95%
Biren Amin Initiates Buy on Rademikibart Developer with Overweight Rating and DCF-Based $7 Price Target on Differentiated Asthma/COPD OpportunityTip Ranks·Jun 26 at 05:05 AMCNTB-0.95%02096+1.51%
Buy Rating Reiterated on Connect Biopharma as Analyst Sees Underappreciated Rademikibart Upside; $7 Price Target MaintainedTip Ranks·Jun 25 at 05:56 AMCNTB-0.95%
Connect Biopharma completes Phase 2 Seabreeze STAT asthma trial enrollment for rademikibartPUBT·Jun 17 at 08:01 AMCNTB-0.95%
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga_article·Jun 2 at 04:09 PMCPHI+5.69%NRXP-2.48%
Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026Market Beat·May 21 at 11:05 PMCNTB-0.95%
Connect Biopharma Holdings (CNTB) Gets a Buy from H.C. WainwrightTip Ranks·May 12 at 11:36 AMCNTB-0.95%XBI-0.54%
Northland Securities Remains a Buy on Connect Biopharma Holdings (CNTB)Tip Ranks·Apr 24 at 08:15 AMCNTB-0.95%SBIO-1.49%
